

Corrigendum to ‘Guideline No. 422a: Menopause: Vasomotor Symptoms, Prescription Therapeutic Agents, Complementary and Alternative Medicine, Nutrition, and Lifestyle’ [J Obstet Gynaecol Can 43 (2021) 1188–1204]

Nese Yuksel, PharmD, Edmonton, AB
Debra Evaniuk, MD, Winnipeg, MB
Lina Huang, MDCM, Montréal, QC
Unjali Malhotra, MD, Vancouver, BC
Jennifer Blake, MD, Ottawa, ON
Wendy Wolfman, MD, Toronto, ON
Michel Fortier, MD, Québec, QC

In “Guideline No. 422a: Menopause: Vasomotor Symptoms, Prescription Therapeutic Agents, Complementary and Alternative Medicine, Nutrition, and Lifestyle,” the statement:

“Menopausal hormone therapy can be safely considered to initiate in women without contraindications who are less than 10 years post—menopause and less than 60 years of age.”

Should read,

“Menopausal hormone therapy can be safely considered to initiate in women without contraindications who are less than 10 years post—menopause or less than 60 years of age.”

This statement appeared correctly in other parts of the guideline, and the error has now been corrected.

The authors would like to apologize for any confusion this caused.

DOI of original article: <https://doi.org/10.1016/j.jogc.2021.08.003>

J Obstet Gynaecol Can 2021;44(2):227

<https://doi.org/10.1016/j.jogc.2021.12.005>

© 2021 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.